Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis

Anti-angiogenic treatments against αvβ3-integrin fail to block tumour growth in the long term, which suggests that the tumour vasculature escapes from angiogenesis inhibition through αvβ3-integrin-independent mechanisms. Here, we show that suppression of β3-integrin in mice leads to the activation o...

Full description

Bibliographic Details
Main Authors: Tim S. Ellison, Samuel J. Atkinson, Veronica Steri, Benjamin M. Kirkup, Michael E. J. Preedy, Robert T. Johnson, Christiana Ruhrberg, Dylan R. Edwards, Jochen G. Schneider, Katherine Weilbaecher, Stephen D. Robinson
Format: Article
Language:English
Published: The Company of Biologists 2015-09-01
Series:Disease Models & Mechanisms
Subjects:
Online Access:http://dmm.biologists.org/content/8/9/1105
Description
Summary:Anti-angiogenic treatments against αvβ3-integrin fail to block tumour growth in the long term, which suggests that the tumour vasculature escapes from angiogenesis inhibition through αvβ3-integrin-independent mechanisms. Here, we show that suppression of β3-integrin in mice leads to the activation of a neuropilin-1 (NRP1)-dependent cell migration pathway in endothelial cells via a mechanism that depends on NRP1's mobilisation away from mature focal adhesions following VEGF-stimulation. The simultaneous genetic targeting of both molecules significantly impairs paxillin-1 activation and focal adhesion remodelling in endothelial cells, and therefore inhibits tumour angiogenesis and the growth of already established tumours. These findings provide a firm foundation for testing drugs against these molecules in combination to treat patients with advanced cancers.
ISSN:1754-8411
1754-8403